IPCALAB1,972.10

Ipca Laboratories Ltd.

· Pharma & Health
₹ CrorePeersTORNTPHARMALKEMJBCHEPHARMABBOTINDIAAJANTPHARMANTHEMGLAXOMEDANTAMcap ₹50,032 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+7.9+11.9
EBITDA+14.6+22.4
Net Income+50.8+50.5
EPS (adj.)+54.7+44.4
Total Assets+5.2+5.6
Total Equity+13.5+11.0
Free Cash Flow-10.3-4.2
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.